No Data
No Data
PuraPharm Schedules Key Board Meeting
Purapharm (01498.HK) expected significant reduction in mid-year net loss.
On August 16th, Gelunhui announced that purapharm (01498.HK) expects to record a comprehensive unaudited loss of no more than about HKD20 million during the mid-term period of 2024, compared with a comprehensive unaudited loss of about HKD37.7 million in the same period last year. The significant reduction in the unaudited comprehensive loss during the mid-term period of 2024 is mainly due to i) the decrease in fair value loss of biological assets related to the Group's planting division, because all impairment has been recognized as of December 31, 2023; and ii) the decrease in administrative expenses, sales and distribution expenses, because the Group operates...
Express News | PuraPharm Corp Ltd - Expected Result Due to Reduction in Administrative Expenses, Among Others
Express News | PuraPharm Corp Ltd Sees Hy Unaudited CONSOL Net Loss of Not More Than HK$20 Mln
Purapharm (01498.HK) will hold a board of directors meeting on August 28 to approve the interim performance.
Purapharm (01498.HK) announced on August 16 that the board of directors meeting will be held on August 28, 2024 to consider and approve the group's mid-term performance for the six months ending on June 30, 2024, and to consider the payment of interim dividends (if any).
PURAPHARM: UPDATES OF FINANCIAL PERFORMANCEFOR THE SIX MONTHS ENDED 30 JUNE 2024
No Data